| Title |
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
|
|---|---|
| Published in |
Gastric Cancer, March 2019
|
| DOI | 10.1007/s10120-018-00909-5 |
| Pubmed ID | |
| Authors |
Yung-Jue Bang, Yoon-Koo Kang, Daniel V. Catenacci, Kei Muro, Charles S. Fuchs, Ravit Geva, Hiroki Hara, Talia Golan, Marcelo Garrido, Shadia I. Jalal, Christophe Borg, Toshihiko Doi, Harry H. Yoon, Mary J. Savage, Jiangdian Wang, Rita P. Dalal, Sukrut Shah, Zev A. Wainberg, Hyun Cheol Chung |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 40% |
| India | 1 | 10% |
| Poland | 1 | 10% |
| Unknown | 4 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 5 | 50% |
| Members of the public | 3 | 30% |
| Scientists | 2 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 138 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 15 | 11% |
| Student > Doctoral Student | 14 | 10% |
| Researcher | 13 | 9% |
| Student > Bachelor | 13 | 9% |
| Student > Ph. D. Student | 11 | 8% |
| Other | 22 | 16% |
| Unknown | 50 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 39% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Biochemistry, Genetics and Molecular Biology | 7 | 5% |
| Agricultural and Biological Sciences | 5 | 4% |
| Nursing and Health Professions | 2 | 1% |
| Other | 7 | 5% |
| Unknown | 56 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 February 2022.
All research outputs
#3,631,499
of 23,340,595 outputs
Outputs from Gastric Cancer
#35
of 607 outputs
Outputs of similar age
#76,222
of 352,035 outputs
Outputs of similar age from Gastric Cancer
#2
of 22 outputs
Altmetric has tracked 23,340,595 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 607 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,035 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.